CD8A and neoplasm: TIGIT contributes to tumor immune evasion through various immunity mechanisms, including inhibiting NK cell-mediated cytotoxicity, suppressing T-cell proliferation, restricting CD8+ T cell activation in the TME, and promoting inflammatory CD4+ T cell responses to impede tumor apoptosis [20].